AI exoskeleton gives wheelchair users the freedom to walk again
"When I'm in the exoskeleton, I feel more free than I do in my daily life," said Laubach. "It gives me the opportunity to walk around and talk to people at eye level. I don't have to look up at people all the time.
"It makes me feel more visible and able to connect with others. One thing I noticed right away, was how inclusive the exoskeleton would be to a wide variety of disabilities. The goal is to have disabled people able to use this exoskeleton to live their daily life out in the world; I can definitely see that happening in the future."
Laubach's story is at the heart of Wandercraft's mission: to help people move through the world with greater walking independence and upright mobility.
Wandercraft's journey began with a personal challenge. Nicolas Simon, the company's co-founder, saw his own family members struggle with mobility due to Charcot-Marie-Tooth disease, a genetic condition. As a student and robotics enthusiast, Simon wanted to create something that could help his brother and others like him walk again. Alongside Matthieu Masselin and Jean-Louis Constanza, who also had a personal connection to the cause, Simon founded Wandercraft in 2012.
Their goal was simple but ambitious: to bring advanced mobility solutions to the estimated 80 million people worldwide who rely on wheelchairs.
Wandercraft's first exoskeleton, Atalante X, is already making a difference in over 100 clinics and research centers worldwide. This device, cleared by the Food and Drug Administration (FDA) and approved in Europe, helps patients take over a million steps each month as part of their rehabilitation. It has already helped hundreds regain some mobility and independence.
But Wandercraft wanted to go further. The new Personal Exoskeleton protoype, now in clinical trials in New York and New Jersey, is designed for daily life, at home, at work, and out in the community. It uses NVIDIA AI to adapt instantly to each user's movements, providing smooth, stable walking on all sorts of surfaces, from sidewalks to carpets. Users control the exoskeleton with a joystick, making it accessible to people with a wide range of abilities.
A big part of Wandercraft's progress comes from its partnership with Nvidia. The team uses Nvidia Isaac Sim, a powerful simulation tool, to test and improve the exoskeleton in virtual environments before real-world trials. They're also exploring Nvidia's healthcare robotics and edge computing platforms to make the device smarter and more responsive.
This technology means the exoskeleton can someday keep up with everyday life, walking at a normal pace, crossing streets, and even handling stairs. As Simon puts it, "It's essential for the exoskeleton to be fast enough that it can be used in the real world. By integrating NVIDIA AI into the device, we can someday enable users to walk at an average pace, cross the road, and go up and down stairs."
Wandercraft's commitment to improving lives goes beyond just building exoskeletons. In the heart of Manhattan, the company has opened Walk in New York by Wandercraft, a state-of-the-art physical therapy practice and Atalante X walk center located at 345 Park Avenue South. This groundbreaking center is the first of its kind in the U.S. and represents a partnership between Wandercraft and licensed physical therapy professionals to help individuals with neurological conditions move more, move better and move again.
At Walk in New York, movement is truly seen as medicine. The center offers personalized screenings with licensed physical therapists, hands-free walking sessions using the Atalante X exoskeleton, and comprehensive neurorehabilitation services. Patients can experience walking again in a safe, professional environment, regardless of their trunk or upper body strength. Each therapy plan is tailored to the individual, and progress is tracked objectively to ensure the best possible outcomes.
The technology at Walk in New York goes beyond exoskeletons. The center features virtual reality systems for real-time movement feedback, mirror therapy to promote motor recovery, advanced gait analysis, and immersive environments that make rehabilitation more engaging and effective.
Walk in New York is also set to become the hub for Wandercraft's Personal Exoskeleton, where individuals will be able to receive their own devices, undergo training, and access ongoing support as this technology becomes available for everyday use. The center's focus on personalized care and innovation makes it a welcoming space for anyone interested in rediscovering mobility, whether for themselves or a loved one.
At Walk in New York, the belief is simple: movement is medicine, and everyone deserves the chance to move through life with confidence and independence.
Wandercraft is working toward FDA approval for the Personal Exoskeleton, with hopes of making it available to millions of wheelchair users in the U.S. and beyond. The company is actively recruiting participants for its clinical trials and is committed to making this technology accessible, with plans for Medicare coverage in the future.
Are you an adult 18 or older with a complete or incomplete motor SCI at or above the T6 vertebra? If so, you might be eligible for our clinical trial. To participate, you'll need a physically able companion to assist you during sessions. If you don't have someone in mind, don't worry, Wandercraft is creating a volunteer network to help connect trial participants with companions. Both patients and companions should be able to speak English or communicate well with a translator. If you meet these criteria, or if you're interested in volunteering as a companion, you can reach out to Wandercraft by emailing them at clinicaltrials@wandercraft.health
Despite all the advances in technology over the past few decades, tens of millions of people still rely on wheelchairs. Wandercraft's Personal Exoskeleton, shaped by the real-life experiences of test pilots like Laubach, is offering a new way forward, one that brings freedom, independence and a renewed sense of possibility.
Laubach's story really shows how powerful this technology can be when it is designed with real people in mind. Wandercraft's Personal Exoskeleton isn't just about robotics or AI; it's about helping people stand tall, connect with others, and live life on their own terms. Every step taken with this device brings that vision closer to reality, making the future of mobility feel more hopeful and within reach than ever before.
In what ways could AI-driven wearable robotics reshape how we think about disability and independence? Let us know by writing us at Cyberguy.com/Contact
For more of my tech tips and security alerts, subscribe to my free CyberGuy Report Newsletter by heading to Cyberguy.com/Newsletter
Follow Kurt on his social channels:
Answers to the most-asked CyberGuy questions:
New from Kurt:
Copyright 2025 CyberGuy.com. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
8 minutes ago
- Medscape
The Hidden Hazards of Generative AI in Medicine
The idiosyncrasies and inadequacies of NHS IT systems — past and present — have driven many a doctor to frustration and despair, as they grapple with yet another new software package whilst trying to manage patient demand. There is an understandable reluctance to embrace change, given that change has rarely delivered the promised efficiencies. It is perhaps unsurprising, therefore, that some healthcare professionals view artificial intelligence (AI) with suspicion. Dr Sara Jamieson Even those who have embraced it and are optimistic about its benefits admit they're unsure about the risks. AI, though, is different from anything that has come before. It is something we should consider embracing and incorporating into our practice as it develops. If we don't, we risk being left behind. Imagine how life might look if we had ignored the introduction of the World Wide Web back in the mid-90s. Similarly, think back to the rapid introduction of telemedicine at the start of the COVID-19 pandemic. This method of consulting with patients, previously frowned upon as too inherently risky, continued even after infection levels subsided. Any new way of practising will bring with it new medicolegal risks, and steps will need to be considered to mitigate these. Whilst beyond the scope of this article, a true understanding of the medicolegal implications of using AI in healthcare requires an understanding of what AI is and how its outputs are generated. This is particularly true for generative AI tools such as ChatGPT. Dr Lucy Hanington According to a survey of over 1000 GPs in the UK, published in BMJ Health & Care Informatics, a fifth of GPs are using generative AI tools such as ChatGPT to help with day-to-day tasks such as writing letters. One in five said they had used these tools in their clinical practice, and of these, nearly a third (28%) said they had used them to suggest a different diagnosis, and a quarter said they had used them to suggest treatment options. Consider this scenario: Dr C, a GP, was running behind schedule and still had three more patients to see. During her next consultation, a 50-year-old patient, Mr B, came in with a set of vague symptoms. Dr C considered a range of possible conditions. Feeling under pressure, she discreetly opened ChatGPT and entered an anonymised summary of the patient's symptoms, requesting a differential diagnosis and possible lab tests. The AI quickly returned a detailed summary of plausible possibilities, including some that Dr C hadn't considered herself. She was impressed and used the suggestions to help her decide on the next steps for Mr B, which included arranging further tests. That night, however, the consultation weighed on her mind, and she couldn't sleep. She knew she hadn't disclosed her use of AI to the patient. She also worried whether she had inadvertently input details that could make Mr B identifiable. She also questioned whether the AI's suggested diagnoses might have influenced her clinical judgement. By morning, Dr C was feeling anxious and uneasy, and decided to call Medical Protection Society (MPS) for advice. A medicolegal consultant advised her to consider whether, objectively, she still agreed with the management plan and could justify it clinically. The GP was also advised to rectify any omissions immediately and to discuss the case with a colleague if helpful. The medicolegal consultant also explained the consent and confidentiality principles around AI use. Benefits Generative AI tools offer many potential benefits for both doctors and patients. Patients may use these tools to understand medical terminology or a diagnosis they have been given. Doctors may find that, when used safely, generative AI can aid diagnosis or identify potential drug interactions. However, generative AI is not always correct. As well as errors or omissions, it can sometimes produce 'hallucinations,' confidently presenting incorrect information as fact. It is incumbent on the clinicians using these tools to ensure that information shared with a patient is reliable and accurate. Bias, whilst not unique to AI, also deserves consideration. The data used by AI tools may be biased due to the inclusion or exclusion of certain information. Outputs may also fail to account for the demographics of a particular patient population. The use of generative AI does not permit doctors to work outside the limits of their competence. There should be no overreliance on the software, and doctors remain ultimately responsible for the decisions they make. Data Protection and Confidentiality Data protection and confidentiality, as highlighted in the earlier scenario, are key considerations. Compliance with General Data Protection Regulation is essential when using generative AI. These tools, by their nature, store, share, and learn from the information entered into them and can be accessed by anyone. Care must be taken not to input any personal patient data. Simply removing a patient's name may not be sufficient to anonymise their information, as other details could make them identifiable. To ensure compliance with data protection legislation, we recommend seeking guidance from: Hospital Data Protection Officers, who may be able to advise on this in a secondary care setting Integrated Care Boards, who may have policies that would be applicable The Information Commissioners Office (ICO) Consent The earlier scenario also highlights the issue of consent. Consent remains a key cornerstone of all doctor-patient interactions. The ICO advises that, for consent to be a lawful basis for processing data when using AI, it must be freely given, specific, and clear. The individual must agree to it, and they must be able to withdraw their consent at any time. AI as an Aid It is important to hold in mind that AI is a tool to assist, rather than replace, the clinician. When it comes to decision-making, AI software can't readily consider the individual wishes and circumstances of the patient. The 'black box' problem — a lack of transparency in how an AI system reaches conclusions — can make it difficult to challenge outputs or detect errors. Ultimately, AI should not replace clinical reasoning, evidence-based medicine, or consultation with colleagues, peers, multidisciplinary teams, specialists, seniors, and supervisors. Training and Continued Learning Clinicians should aim to be literate in AI, understand its basis and governance, and know how to use it safely. We would encourage all clinicians to incorporate learning on the topic as part of their annual development plans. A multitude of resources on AI are available across medical colleges and institutions. We would also recommend watching the recordings of the recent MPS Foundation AI symposia. A white paper, published by the MPS Foundation, the Centre for Assuring Autonomy at the University of York, and the Improvement Academy hosted at the Bradford Institute for Health Research, offers further useful guidance for doctors to consider on AI use. Conclusion Like it or not, AI is here to stay. Readers should consider its potential benefits while remaining alive to its limitations and risks. Doctors should also ensure they continue to work in a manner consistent with General Medical Council guidance and relevant legislation. If in doubt about using AI tools and their medicolegal implications, doctors can contact MPS or their medical defence organisation to request advice. This article is published as part of an editorial collaboration between Medscape UK and MPS that aims to deliver medicolegal content to help healthcare professionals navigate the many challenges they face in their clinical practice. Dr Sara Jamieson, MBBS, trained in psychiatry before joining MPS in 2016 as a medicolegal consultant. She has disclosed no relevant financial relationships. Dr Lucy Hanington, BMBCh, MRCPCH, has worked as a medicolegal consultant at MPS since 2016. She has disclosed no relevant financial relationships.
Yahoo
10 minutes ago
- Yahoo
‘Life-threatening': Thousands of bogus online pharmacies selling fake Ozempic jabs
Warnings have been issued over fake weight loss jabs that could be 'life-threatening' after thousands of fraudulent online pharmacies were uncovered. Fake versions of Ozempic, a popular brand of weight loss jab, were being sold for as little as £13.70 per dose, along with counterfeit versions of other brands, including Rybelsus and Metformin pills, being offered from 24p. The UK's medicines regulator said taking bogus medications could not only make people ill, but in some cases could be fatal. Researchers from Avast, a cybersecurity brand of the company Gen, who conducted the investigation, warned of the 'dangerous' threat of the global scam involving more than 5,000 fake pharmacy sites this year, which they say are being run by criminal networks. It comes amid the rapid rise of weight-loss medication in the UK – with around 1.5 million people, 4 per cent of households, currently using them. Gen also found fake Viagra, a medicine used to treat erection issues, and unregulated fertility pills being sold. The company said lab tests found no active ingredient in a third of the drugs tested. Andy Morling, deputy director of criminal enforcement at the Medicines and Healthcare products Regulatory Agency (MHRA), told The Independent: 'Buying medicines from illegal suppliers significantly increases the risk of receiving products that are either falsified or not licensed for use in the UK. Products purchased in this way will not meet the MHRA's strict quality and safety standards. 'Medicines obtained from illegally trading sources can not only fail to work, but they can also make you very sick. In some cases, they may contain toxic substances or dangerously high levels of the correct active ingredient, with potentially fatal consequences.' The researchers warned that the 'alarmingly' polished websites, complete with bogus customer service information, detailed product pages, and looked similar to legitimate online pharmacies. But many were detected as fakes because they used AI to create reviews, health blogs, live chat support and manipulated search results. As well as the health implications, the researchers said UK customers risked their details and identity being stolen by the sites. Siggi Stefnission, cyber safety chief technology officer at Gen, warned: 'Purchasing pharmaceuticals from untrusted online retailers is a serious danger, both to individual health and to someone's digital safety. 'From a public health perspective, counterfeit or unregulated drugs can be ineffective or even life-threatening. It's critical that consumers only use licensed, reputable online pharmacies to protect themselves from cybercrime and potential physical harm.' The popularity of weight-loss jabs has soared in the past year, with the NHS's top doctor, Sir Stephen Powis, saying they could soon become among the most commonly used drugs. Both Ozempic and Rybelsus, which have the active ingredient semaglutide, are not licensed as a weight loss treatment. Instead they are designed to treat people with type 2 diabetes but both are sometimes prescribed off-label to treat weight loss. However, popular weight loss jabs Wegovy, which has the same active ingredient, and Mounjaro, which uses the active ingredient tirzepatide, are both licensed in the UK for the treatment of weight loss. Gen explained that criminals are taking advantage of people looking for a fast and discreet way to get high-demand weight loss treatment, among other medications that are often sought quickly, privately, or at a lower cost. Alongside the vast network of more than 5,000 web domains selling the in-demand drugs fraudulently, Gen said, this year alone, it has already blocked 1 million attacks coming from these sites against unsuspecting online shoppers. Laura Wilson, director at Royal Pharmaceutical Society, said fake and illegal online pharmacies 'are a growing threat to patient safety'. She explained that fraudulent medicines may be out of date, substandard or contain 'dangerous' substances. Gen said its team is currently working on testing fake medications to work out what exactly they are made of. The company advised consumers to watch out for low-cost offers for prescription-only drugs, missing contact information, requests for cryptocurrency payments, unsecured checkout processes, and prompts for sensitive personal, medical, or financial data. Novo Nordisk, the company that makes Ozempic and Rybelsus, said it was aware that counterfeit Ozempic products are being sold in the UK and is working with health authorities, including the MHRA, to investigate the 'critical issue'. It advised people to examine packaging and pens closely before using them. Mr Morling said the MHRA is cracking down on the issue of fake medicines and pharmacies, with offenders potentially facing criminal investigation and prosecution. The Independent has approached Pfizer, the company that makes Viagra, for comment.
Yahoo
36 minutes ago
- Yahoo
ADCs Set for Growth Amid Regulatory Evolutions and Technological Advances
The Antibody Drug Conjugates Market presents opportunities in developing novel ADC platforms, expanding into new cancer types, and leveraging biomarker-driven patient selection. Growth is driven by increasing demand for targeted therapies, technological advancements, and investment in R&D despite competition and regulatory challenges. Antibody Drug Conjugates Market Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates: Market Share, and Growth Analysis by Product Type (Monoclonal Antibodies, Small Molecule Drugs), Application, End User, Technology" report has been added to Antibody Drug Conjugates Market size is valued at USD 11.1 billion in 2025 and is projected to reach USD 42.2 billion by 2033, registering a compound annual growth rate (CAGR) of 18.2% over the forecast period. The Antibody Drug Conjugates (ADCs) Market focuses on the development and commercialization of targeted cancer therapies. ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, delivering the drug directly to cancer cells while minimizing damage to healthy tissues. The market is driven by the increasing demand for targeted cancer therapies with improved efficacy and safety profiles. The market encompasses various ADC platforms, including linkers, payloads, and conjugation market is segmented based on target antigen, payload, linker, and application. The major target antigens include HER2, CD30, and CD33. The market caters to a diverse range of cancer types, including breast cancer, lymphoma, and leukemia. The market is characterized by intense competition among pharmaceutical and biotechnology companies, with a focus on developing novel ADC platforms and expanding the therapeutic applications of Antibody Drug Conjugates Market is subject to stringent regulatory requirements and evolving guidelines regarding cancer therapies. The market is also influenced by the increasing complexity of cancer biology and the need for highly specific and potent ADCs. The market is expected to continue its growth trajectory, driven by the increasing demand for targeted cancer therapies and the development of innovative ADC Insights: Antibody Drug Conjugates Market Development of novel ADC platforms with improved stability and efficacy. Expansion of ADC applications to solid tumors and other cancer types. Increasing use of biomarker-driven patient selection for ADC therapy. Growing interest in combination therapies involving ADCs and other cancer treatments. Rising adoption of next-generation sequencing and other technologies to optimize ADC development. Increasing prevalence of cancer and the need for effective treatments. Growing demand for targeted cancer therapies with improved safety profiles. Technological advancements in ADC development and conjugation technologies. Rising investment in research and development by pharmaceutical and biotechnology companies. Increasing availability of funding and partnerships for ADC development projects. High cost of ADC development and manufacturing. Complexity of ADC design and optimization. Challenges in delivering the payload to cancer cells and minimizing off-target effects. Evolving regulatory requirements and intellectual property considerations. Competition from alternative cancer therapies, such as immunotherapy and cell therapy What's Included in the Report? Global Antibody Drug Conjugates market size and growth projections, 2024-2034 North America Antibody Drug Conjugates market size and growth forecasts, 2024-2034 (United States, Canada, Mexico) Europe market size and growth forecasts, 2024-2034 (Germany, France, United Kingdom, Italy, Spain) Asia-Pacific Antibody Drug Conjugates market size and growth forecasts, 2024-2034 (China, India, Japan, South Korea, Australia) Middle East Africa Antibody Drug Conjugates market size and growth estimate, 2024-2034 (Middle East, Africa) South and Central America Antibody Drug Conjugates market size and growth outlook, 2024-2034 (Brazil, Argentina, Chile) Antibody Drug Conjugates market size, share and CAGR of key products, applications, and other verticals, 2024-2034 Short- and long-term Antibody Drug Conjugates market trends, drivers, challenges, and opportunities Antibody Drug Conjugates market insights, Porter's Five Forces analysis Profiles of 5 leading companies in the industry - overview, key strategies, financials, product portfolio and SWOT analysis Latest market news and developments Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2033 Estimated Market Value (USD) in 2025 $11.1 Billion Forecasted Market Value (USD) by 2033 $42.2 Billion Compound Annual Growth Rate 18.2% Regions Covered Global Antibody Drug Conjugates Market Segmentation By Product Type: Monoclonal Antibodies Small Molecule Drugs By Application: Oncology Autoimmune Diseases Infectious Diseases By End User: Hospitals Specialty Clinics Research Institutes By Technology: Chemical Linkers Bioconjugation Techniques By Distribution Channel: Direct Sales Distributors By Geography: North America (USA, Canada, Mexico) Europe (Germany, UK, France, Spain, Italy, Rest of Europe) Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC) The Middle East and Africa (Middle East, Africa) South and Central America (Brazil, Argentina, Rest of SCA) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antibody Drug Conjugates Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
